Daniel R. Chevallard, CFO of LENZ Therapeutics ($LENZ), bought shares on the open market twice in the past year, totaling about $50,000. His most recent purchase was on November 7, 2025. These buys rank him 2,988th out of nearly 5,000 insiders, below the average of $1.5 million per buyer and 3.3 transactions. He reported no open market sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 27, 2026 | LENZ Therapeutics, Inc. | $LENZ | Chevallard Daniel R. | Chief Financial Officer | P | Common Stock | 7500 | $8.57 | 12,886.0000 | 31,289,969 | 139.25% | 0.02% |
| Jan. 2, 2026 | LENZ Therapeutics, Inc. | $LENZ | Chevallard Daniel R. | Chief Financial Officer | A | Restricted Stock Unit | 14000 | $0.00 | 14,000.0000 | 31,289,969 | 9999.99% | 0.04% |
| Jan. 2, 2026 | LENZ Therapeutics, Inc. | $LENZ | Chevallard Daniel R. | Chief Financial Officer | A | Stock Option (right to buy) | 84200 | $0.00 | 84,200.0000 | 31,289,969 | 9999.99% | 0.27% |
| Nov. 7, 2025 | LENZ Therapeutics, Inc. | $LENZ | Chevallard Daniel R. | Chief Financial Officer | P | Common Stock | 20 | $22.71 | 3,208.0000 | 31,289,969 | 0.63% | 0.00% |
| Nov. 7, 2025 | LENZ Therapeutics, Inc. | $LENZ | Chevallard Daniel R. | Chief Financial Officer | P | Common Stock | 2178 | $22.76 | 5,386.0000 | 31,289,969 | 67.89% | 0.01% |
| Jan. 9, 2025 | LENZ Therapeutics, Inc. | $LENZ | Chevallard Daniel R. | Chief Financial Officer | A | Stock Option (right to buy) | 70444 | $0.00 | 70,444.0000 | 0 | 9999.99% | 0.00% |
| May 14, 2024 | LENZ Therapeutics, Inc. | $LENZ | Chevallard Daniel R. | Chief Financial Officer | P | Common Stock | 3188 | $15.68 | 3,188.0000 | 0 | 9999.99% | 0.00% |
| March 21, 2024 | LENZ Therapeutics, Inc. | $LENZ | Chevallard Daniel R. | Chief Financial Officer | A | Stock Option (right to buy) | 200000 | $0.00 | 200,000.0000 | 0 | 9999.99% | 0.00% |
| March 12, 2024 | Viracta Therapeutics, Inc. | $VIRX | Chevallard Daniel R. | CFO and COO | A | Stock Option (Right to Buy) | 200000 | $0.00 | 200,000.0000 | 39,272,434 | 9999.99% | 0.51% |
| Feb. 25, 2024 | Viracta Therapeutics, Inc. | $VIRX | Chevallard Daniel R. | CFO and COO | M | Restricted Stock Units | 6889 | $0.00 | 34,444.0000 | 0 | 16.67% | 0.00% |
| Feb. 27, 2024 | Viracta Therapeutics, Inc. | $VIRX | Chevallard Daniel R. | CFO and COO | S | Common Stock | 3405 | $0.73 | 102,306.0000 | 0 | 3.22% | 0.00% |
| Feb. 25, 2024 | Viracta Therapeutics, Inc. | $VIRX | Chevallard Daniel R. | CFO and COO | M | Common Stock | 6889 | $0.00 | 105,711.0000 | 0 | 6.97% | 0.00% |